SFAs AND CVD
More recent meta-analyses of high compared with low intakes of SFAs fail to find any increased CVD risk. Siri-Tarino et al. (3) compared extreme quantiles of SFA intake and found RRs not different from 1.0. However, it has become obvious that the different fatty acids derived from different foods do not have the same biological effects, and that the food matrix within which they are delivered modifies their effect. So the health effects of any food matrix rich in SFAs cannot be predicted on the basis of the content of ''total SFAs'' given on the nutrient content label. There is a need to view the health effect of ''whole foods'' and to use biomarkers to improve the validity of the habitual food intake registered in observational studies and adherence in RCTs.
Chowdhury et al. (4) examined the effect of SFAs based on a meta-analysis of 17 observational studies with fatty acid biomarkers and 27 randomized controlled trials (RCTs) of fatty acid supplementation. In the observational studies, RRs for coronary disease were no different for SFAs, n-6 PUFAs, and MUFAs when the top and bottom thirds of baseline dietary fatty acid intake or circulating fatty acids were compared. The metaanalysis of RCTs with hard CVD endpoints reached the same conclusion. Another meta-analysis of RCTs even suggested that replacement of SFAs with pure n-6 PUFAs might increase CVD risk and mortality (5) .
DAIRY AND RISK OF CVD AND TYPE 2 DIABETES
In recent years, a substantial body of research has investigated the effects of dairy and dairy fat on risks of CVD, type 2 diabetes, and obesity. A dose-response meta-analysis of prospective studies indicates that milk intake is not associated with total mortality but may be inversely associated with overall CVD risk (6) .
Reliance on self-reported dietary intakes poses substantial problems with validity, and the development of objective biomarkers to distinguish between different food-derived fatty acids represents a major advantage; pentadecanoic acid (15:0), heptadecanoic acid (17:0), and trans palmitoleic acid (trans 16:1n-7) can be used as biomarkers for dairy intake. The literature has generated mixed results with regard to risk of stroke, but the most comprehensive study from 2 large U.S. cohorts (Health Professionals Follow-Up Study: 51,529 men; Nurses' Health Study: 121,700 women) using biomarkers of dairy fat (pentadecanoic acid, heptadecanoic acid, and trans palmitoleic acid) reports results for stroke in this issue of the Journal (7). After relevant adjustments, no significant associations with total stroke were seen for any of the 3 biomarkers. The results were similar for ischemic and hemorrhagic stroke subtypes, and the results remained in sensitivity analyses.
SFAs have also been associated with increased risk of type 2 diabetes, which is a major risk factor for CVD. However, metaanalyses of observational studies based on self-reported dietary intake failed to find that dairy increases the risk of type 2 diabetes (8, 9) . In a meta-analysis of 17 cohort studies, there was a modest but significant inverse relation between intakes of total dairy products, low-fat dairy products, and cheese and risk of type 2 diabetes (9).
BIOMARKERS OF DAIRY AND DIABETES RISK
A case-cohort analysis was conducted based on the European Prospective Investigation into Cancer and Nutrition-InterAct study in 12,403 individuals with incident type 2 diabetes, and fatty acids were measured in plasma phospholipids (10) . Whereas even-chain SFAs were positively associated with incident type 2 diabetes, the odd-chain SFAs pentadecanoic acid and heptadecanoic acid were inversely associated with incident type 2 diabetes (HRs: 0.79 and 0.67, respectively). However, whereas this study adds further to evidence of a diabetesprotective effect of dairy products, it does not present any mechanism nor does it provide information about whether it is the SFAs or other components within the food matrix of dairy that mediate the effects. In contrast, also in this issue of the Journal, Santaren et al. (11) confirm that serum concentrations of pentadecanoic acid were associated with a 27% risk of diabetes (OR: 0.73; P ¼ 0.02), and the association remained after adjustment for BMI and waist circumference. This suggests that the effect is independent of body fatness, an important cause of type 2 diabetes. Santaren et al. also used frequently sampled intravenous glucose tolerance tests to measure insulin sensitivity (S I ) and b cell function (Disposition Index), and they found that concentrations of pentadecanoic acid were positively associated with both measures in fully adjusted models. These associations were substantially weakened by adjustment for obesity indexes. The authors correctly state that the mechanism underlying the inverse relation of pentadecanoic acid with diabetes risk is not known, and that it could be either an effect of fatty acid or attributable to other beneficial components within the dairy matrix.
CONCLUSIONS
The totality of evidence does not support that dairy SFAs increase the risk of coronary artery disease or stroke or CVD mortality. In contrast, lean dairy is clearly associated with decreased risk of type 2 diabetes, and this effect is partly independent of any effect of body fat loss. In addition, lean dairy does not increase body fatness but tends to preserve lean body tissue. There is no evidence left to support the existing public health advice to limit consumption of dairy to prevent CVD and type 2 diabetes. Cheese and other dairy products are, in fact, nutrientdense foods that give many people pleasure in their daily meals. 
